CCL17-CCR4轴对突变的STAT6介导的微环境重塑和复发性/反射性扩散性大B细胞淋巴瘤的治疗阻力至关重要
Madelyn J Abraham1, Cynthia Guilbert2, Natascha Gagnon3
1McGill University Montreal, Quebec Canada.
Cancer immunology research
|December 29, 2025
概括
扩散型大B细胞淋巴瘤 (DLBCL) 中的STAT6突变通过通过CCR4吸引CD4+T细胞来驱动治疗耐药性. 抑制CCR4恢复了对多克索鲁比的敏感性,将其确定为复发性/耐药DLBCL的潜在治疗标.
科学领域:
- 血液学-瘤学 血液学-瘤学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 复发性和耐火性扩散性大B细胞淋巴瘤 (rrDLBCL) 构成了重大的临床挑战,对于对标准疗法的耐药性患者,治疗选择有限.
- 信号转换器和转录激活器6 (STAT6) 的功能获取突变,特别是D419,在rrDLBCL中是复发性的,并且与增加的CCL17 (TARC) 化学激素产生和CD4+ T细胞透有关.
研究的目的:
- 研究STAT6 D419突变在DLBCL中驱动治疗耐药性的作用.
- 阐明STAT6突变影响T细胞透和影响治疗反应的机制.
- 为了确定 STAT6 突变 rrDLBCL 的潜在治疗点.
主要方法:
- 开发一种STAT6 D419N突变DLBCL小鼠模型,复制人类疾病特征.
- 活体功能测试,以评估CD4+T细胞对瘤细胞的化学吸引力.
- 在小鼠模型中使用小分子抗剂抑制CCR4.
- 用PhenoCycler对人类rrrDLBCL样本进行成像,以分析细胞相互作用.
主要成果:
- 在STAT6 D419N小鼠模型中,-STAT6的增加,CD4+T细胞的入侵,以及对多克索鲁比的耐药性.
- 在STAT6 D419N瘤中的CD4+ T细胞显示了CCL17受体,CCR4.4的更高表达.
- STAT6 D419N瘤细胞直接吸引了CCR4+ CD4+ T细胞,CCR4的抑制减少了T细胞透,恢复了多克索鲁素的敏感性.
- 具有STAT6 D419突变的人类rrrDLBCL样本显示基-STAT6的增加和瘤细胞和CD4+/CCR4+T细胞之间的增强相互作用.
结论:
- STAT6 D419突变通过培养吸引CCR4表达CD4+T细胞的环境,促进DLBCL中的治疗耐药性.
- CCR4充当这种相互作用的关键调解者,是STAT6突变的rrDLBCL的一个有前途的治疗点.
- 向CCR4可以克服治疗耐药性,并改善这种特定DLBCL亚型患者的治疗结果.
相关概念视频
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
B Cell Activation and Differentiation
15.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.8K
T Cell Activation and Clonal Selection
14.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.5K
The JAK-STAT Signaling Pathway
11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.8K


